Drug Profile

Evorpacept - ALX Oncology

Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148

Latest Information Update: 26 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alexo Therapeutics
Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; University of California; Zymeworks
Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia; Gastric cancer
New Molecular Entity Yes

Phase II/III Adenocarcinoma
Phase II Colorectal cancer; Oropharyngeal cancer; Squamous cell cancer
Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
No development reported Breast cancer; Urogenital cancer

11 Mar 2026 Alx Oncology has patent protection for evorpacept
28 Feb 2026 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA
28 Feb 2026 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com